Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

This next-generation GLP-1 therapy leverages the benefits of GLP-1s, such as enhanced insulin secretion and appetite reduction ... Its less frequent dosing, more selective IL-13 inhibition, and strong ...

Its weekly dosing offers a significant advantage over daily basal insulin, potentially reducing the treatment ... For this application, ImmTOR consists of SEL-110.36, an inhibitor of uricase-specific ...

This next-generation GLP-1 therapy leverages the benefits of GLP-1s, such as enhanced insulin secretion and ... Its less frequent dosing, more selective IL-13 inhibition, and strong efficacy ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering hundreds of diseases, drugs, and markets and 11 integrated data sets that span ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

New integration delivers personalised insulin dosing advice, improving care for people with diabetes and enhancing healthcare provider insights. COPENHAGEN, Denmark and PALO ALTO, Calif., ...

and digital therapeutic technologies to enhance access for people with Type 1 and Type 2 diabetes requiring advanced bolus insulin dosing support in their daily management. This launch is ...